Newsroom
23 press releases and 54 media coverage stories
Drug Discovery World: Event highlights in 2024 so far
Drug Discovery World
ISCT 2024 showcased the latest in cell and gene therapy (CGT). A key focus was on industry sustainability. Josh Ludwig from ScaleReady emphasized the need for operational efficiency over simply expanding space. Optimizing processes like inventory management is crucial for reducing costs and environmental impact.
Read the article : Drug Discovery World: Event highlights in 2024 so farShare: Drug Discovery World: Event highlights in 2024 so far
Pharma’s Almanac: How can Life Science Technology Providers Support the Pharmaceutical Industry?
Pharma’s Almanac
Digital transformation in pharma needs careful planning, according to Josh Ludwig of ScaleReady. User-friendly technology and streamlined operations are key. Technology providers must partner with pharma companies to ensure successful implementation.
Read the article : Pharma’s Almanac: How can Life Science Technology Providers Support the Pharmaceutical Industry?Share: Pharma’s Almanac: How can Life Science Technology Providers Support the Pharmaceutical Industry?
Pharma’s Almanac: Current Investment Trends in the Pharmaceutical Industry
Pharma’s Almanac
The surge in CAR-T and gene therapy approvals is driving pharma investment in cell therapy manufacturing. Josh Ludwig, ScaleReady's Global Director of Commercial Operations, discusses the success of therapies like Carvykti underscores the need for robust manufacturing. This growing demand will fuel further investment in both therapies and the supporting manufacturing technologies.
Read the article : Pharma’s Almanac: Current Investment Trends in the Pharmaceutical IndustryShare: Pharma’s Almanac: Current Investment Trends in the Pharmaceutical Industry
BioProcess International: ScaleReady launches $20m advanced therapy grant program
BioProcess International
ScaleReady, in collaboration with Wilson Wolf, Bio-Techne, and CellReady, has launched a ‘G-Rex®’ grant program aimed at advancing CGTs.
Read the article : BioProcess International: ScaleReady launches $20m advanced therapy grant programShare: BioProcess International: ScaleReady launches $20m advanced therapy grant program
The Medicine Maker: Introducing the Experts
The Medicine Maker
Industry leaders are uniting to drive the future of cell and gene therapy manufacturing. Experts like Josh Ludwig of ScaleReady are at the forefront of implementing automation and digital solutions to overcome complex challenges in the sector. From streamlining operations to accelerating time-to-market, these advancements are poised to revolutionize the industry.
Read the article : The Medicine Maker: Introducing the ExpertsShare: The Medicine Maker: Introducing the Experts
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing
PR Newswire
The G-Rex® Grant Program will provide academic and commercial institutions engaged in IND enabling pre-clinical research, process development, and/or ongoing GMP manufacturing of cell and gene therapies with the material resources and services needed to implement or optimize a highly efficient G-Rex® based cell manufacturing platform.
Read the release : ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and ManufacturingShare: ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing
Fierce Pharma: Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing
Fierce Pharma
The final installment of "The Top Line" series dives deep into the cutting-edge world of cell and gene therapy manufacturing. Join host Fraiser Kansteiner, Josh Ludwig and other industry experts as they explore innovative production approaches and discuss how to overcome the challenges of bringing these life-saving therapies to market.
Read the article : Fierce Pharma: Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturingShare: Fierce Pharma: Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing
BioProcess International: CAR-T Therapy Manufacturing Lessons from the Automotive Industry
BioProcess International
CAR-T therapy has promise but manufacturing is slow and expensive. In this article, ScaleReady's Josh Ludwig suggests CAR-T manufacturing can learn from the auto industry's assembly-line approach to improve efficiency and make these therapies more accessible.
Read the article : BioProcess International: CAR-T Therapy Manufacturing Lessons from the Automotive IndustryShare: BioProcess International: CAR-T Therapy Manufacturing Lessons from the Automotive Industry
Drug Discovery World: Looking Ahead for Cell and Gene Therapy
Drug Discovery World
Drug Discovery World discusses the future of the cell and gene therapy sector with industry experts, including ScaleReady’s Josh Ludwig, who predict what to expect in 2024 and beyond.
Read the article : Drug Discovery World: Looking Ahead for Cell and Gene TherapyShare: Drug Discovery World: Looking Ahead for Cell and Gene Therapy
Pharma’s Almanac: How Can Biopharma Demonstrate Its Commitment to ESG in Manufacturing?
Pharma's Almanac
In this edition of the Pharma's Almanac quarterly roundtable questionnaire, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss how pharmaceutical and biopharmaceutical companies can demonstrate their commitment to ESG principles in manufacturing.
Read the article : Pharma’s Almanac: How Can Biopharma Demonstrate Its Commitment to ESG in Manufacturing?Share: Pharma’s Almanac: How Can Biopharma Demonstrate Its Commitment to ESG in Manufacturing?
Pharma’s Almanac: What Strategies Accelerate Time-to-market Without Compromising Quality?
Pharma's Almanac
In this edition of the Pharma's Almanac quarterly roundtable questionnaire, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss the increasing pressure to reduce time-to-market. The share strategies to accelerate product development and commercialization without compromising quality.
Read the article : Pharma’s Almanac: What Strategies Accelerate Time-to-market Without Compromising Quality?Share: Pharma’s Almanac: What Strategies Accelerate Time-to-market Without Compromising Quality?
BioSpace: How Cell and Gene Therapy Manufacturing Will Evolve in 2024
BioSpace
Key figures at Phacilitate’s Advanced Therapies Week emphasized the power of sharing knowledge to create standardized, scalable processes in cell and gene therapy manufacturing. ScaleReady is proud to embrace this approach, especially in our partnership with Luminary Therapeutics.
Read the article : BioSpace: How Cell and Gene Therapy Manufacturing Will Evolve in 2024Share: BioSpace: How Cell and Gene Therapy Manufacturing Will Evolve in 2024
